title: Evaluation of WO2013076170: the use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis.
abstract: Inhibition of dihydroorotate dehydrogenase (DHODH) modulates pyrimidine biosynthesis. Effective inhibitors are immunomodulatory drugs clinically useful in the treatment of diseases such as rheumatoid arthritis, psoriatic arthritis and multiple sclerosis. There is limited evidence of their potential utility in treating psoriasis. This patent application claims topical formulations of the non-hepatotoxic DHODH inhibitor 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for use in the treatment of psoriasis. This inhibitor had previously been claimed to be useful in treating various autoimmune disease.
authors: Norman Consulting , 18 Pink Lane, Burnham, Bucks, SL1 8JW , UK peter.norman2@btinternet.com.
authors: Peter
authors: P
authors: Norman
mesh_terms: D000287:Administration, Topical; D000814:Aniline Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000090722:Dihydroorotate Dehydrogenase; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000037:antagonists & inhibitors*; D010330:Patents as Topic; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: C587986:2-((3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino)nicotinic acid; D000814:Aniline Compounds; D000090722:Dihydroorotate Dehydrogenase; D004791:Enzyme Inhibitors; D009539:Nicotinic Acids; D044925:Oxidoreductases Acting on CH-CH Group Donors